REG - GSK PLC - Result of AGM

GSKAnnouncement

Yesterday 18:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF3149Da&default-theme=true

RNS Number : 3149D  GSK PLC  06 May 2026

 

 

 

Issued: 6 May 2026, London UK

 

Results of 26(th) Annual General Meeting

 

 

 

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on
Wednesday 6 May 2026 at the London Marriott Hotel Grosvenor Square, Grosvenor
Square, London, W1K 6JP. Shareholders were able to join the meeting in person
or virtually via the Lumi Global website and Zoom.

 

All valid proxy votes (whether submitted electronically or in hard copy form)
were included in the poll taken at the meeting.

 

All 25 resolutions were passed and decided upon by a poll. The table below
shows the results for each resolution. The full text of the resolutions is
contained in the Notice of AGM published on 25 March 2026, which is available
on GSK's website at www.gsk.com (http://www.gsk.com) .

 

 Resolution                                                                           Total votes for((1)(2))  %      Total votes against((2))  %     Total votes cast  % of Issued Share Capital voted((3))  Votes withheld((4))
 1       Receive and adopt the 2025 Annual Report                                     3,073,839,952            99.25  23,182,191                0.75  3,097,022,143     76.38%                                8,652,004
 2       Approve the Annual report on remuneration                                    2,986,046,185            96.74  100,644,457               3.26  3,086,690,642     76.12%                                18,986,231
 3       Approve the Remuneration policy                                              3,066,582,993            98.96  32,182,945                1.04  3,098,765,938     76.42%                                6,914,570
 4       Election of Luke Miels                                                       3,081,325,569            99.37  19,501,818                0.63  3,100,827,387     76.47%                                4,845,132
 5       Re-election of Sir Jonathan Symonds                                          3,079,744,123            99.32  21,127,306                0.68  3,100,871,429     76.47%                                4,793,341
 6       Re-election of Julie Brown                                                   3,069,722,312            99.00  31,102,814                1.00  3,100,825,126     76.47%                                4,848,203
 7       Re-election of Elizabeth McKee Anderson                                      3,042,023,812            98.52  45,732,363                1.48  3,087,756,175     76.15%                                17,906,882
 8       Re-election of Charles Bancroft                                              3,070,002,110            99.43  17,646,639                0.57  3,087,648,749     76.15%                                18,018,954
 9       Re-election of Dr Hal Barron                                                 3,080,985,163            99.37  19,595,495                0.63  3,100,580,658     76.47%                                5,088,510
 10      Re-election of Dr Anne Beal                                                  3,048,091,490            98.71  39,715,257                1.29  3,087,806,747     76.15%                                17,858,160
 11      Re-election of Wendy Becker                                                  3,031,625,476            98.18  56,091,438                1.82  3,087,716,914     76.15%                                17,946,122
 12      Re-election of Dr Harry C Dietz                                              3,094,560,703            99.80  6,160,152                 0.20  3,100,720,855     76.47%                                4,943,572
 13      Re-election of Dr Jeannie Lee                                                3,095,593,233            99.84  5,084,831                 0.16  3,100,678,064     76.47%                                4,985,598
 14      Re-election of Dr Gavin Screaton                                             3,095,403,626            99.83  5,240,337                 0.17  3,100,643,963     76.47%                                5,019,966
 15      Re-election of Dr Vishal Sikka                                               3,095,036,695            99.82  5,513,088                 0.18  3,100,549,783     76.47%                                5,111,280
 16      Re-appointment of the auditor                                                3,099,113,772            99.94  1,891,083                 0.06  3,101,004,855     76.48%                                4,664,323
 17      Remuneration of the auditor                                                  3,098,976,181            99.94  1,736,335                 0.06  3,100,712,516     76.47%                                4,949,197
 18      Authority for the company to make donations to political organisations and   3,039,847,574            98.91  33,534,985                1.09  3,073,382,559     75.80%                                32,288,122
         incur political expenditure
 19      Authority to allot shares                                                    2,999,108,776            96.74  100,960,760               3.26  3,100,069,536     76.45%                                5,592,295
 20      Disapplication of pre-emption rights - general power((5))                    3,046,584,734            98.32  51,962,919                1.68  3,098,547,653     76.42%                                7,072,535
 21      Disapplication of pre-emption rights - in connection with an acquisition or  3,059,992,748            98.75  38,710,772                1.25  3,098,703,520     76.42%                                6,947,940
         specified capital investment((5))
 22      Authority for the company to purchase its own shares((5))                    3,093,867,095            99.82  5,669,416                 0.18  3,099,536,511     76.44%                                6,127,609
 23      Exemption from statement of senior statutory auditor's name                  3,079,861,236            99.81  5,739,421                 0.19  3,085,600,657     76.10%                                20,038,163
 24      Authority for reduced notice of a general meeting other than an AGM((5))     2,911,856,203            93.98  186,503,587               6.02  3,098,359,790     76.41%                                7,285,017
 25      Approve the amended Articles of Association((5))                             3,065,959,469            99.40  18,375,929                0.60  3,084,335,398     76.07%                                21,304,284

 

 

Notes:

 

(1)      The "for" votes include those giving the Chair discretion.

(2)      Votes "for" and "against" are expressed as a percentage of the
total votes cast.

(3)      The Company's issued share capital as at 1 May 2026 consisted of
4,054,826,603 shares of 31 ¼ pence each ('Ordinary Shares') excluding
Ordinary Shares held in Treasury. Every shareholder has one vote for every

Ordinary Share held.

(4)      A "vote withheld" is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a resolution.

(5)      Indicates Special Resolutions requiring a 75% majority of votes
cast.

 

 

The following table provides further information on participation in the AGM:

 

                                                                          GSK's 26(th) AGM            GSK's 25(th) AGM

                                                                          (Hybrid meeting)            (Hybrid meeting)

                                                                          (2026)                      (2025)
 Issued share capital (excluding Treasury Shares)                         4,054,826,603               4,109,037,095
 Total votes cast and votes withheld lodged as a % of GSK's issued share  76.59%                      74.21%
 capital (excluding Treasury Shares)
 Total shareholder population                                             55,305                      57,405
 Total number of proxies lodged                                           2,475                       2,617
 Number of shareholders in attendance                                     117 in person               130 in person

                                                                          17 participated virtually   25 participated virtually
 % of shareholders who lodged proxies                                     4.48%                       4.56%

 

 

The above poll results will shortly be available on the company's website at
www.gsk.com (http://www.gsk.com) .

 

In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's
(FCA) Listing Rules, a copy of the resolutions, other than those concerning
ordinary business, will be submitted to the FCA and will, in due course, be
available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

 

V A Whyte

Company Secretary

6 May 2026

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGAFMRTMTBMBLF



            Copyright 2019 Regulatory News Service, all rights reserved